Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has initiated patient recruitment for Group Two of its ongoing human clinical study of the Ocumetics Lens, an accommodating intraocular lens designed to potentially eliminate the need for corrective lenses. The announcement marks a significant step forward in the company's clinical development program.
Unlike the Group One study, which focused solely on safety, the Group Two study aims to evaluate both safety and visual performance, specifically near and distance vision, of the next-generation Ocumetics Lens. Patients enrolled in this phase will receive the latest iteration of the lens, which incorporates design advancements and will be implanted using an enhanced delivery system.
The Mexico City facility, which successfully conducted Group One surgeries in Fall 2025, has begun identifying eligible patients for the upcoming surgeries scheduled for Fall 2026. This progression follows encouraging results from Group One, where clinical outcomes met and exceeded expectations regarding safety, performance, and handling. As Group One patients reach their 12-month follow-up visits, the company is gathering longer-term safety and efficacy data that will inform future development.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about advancing to Group Two. "We are extremely excited to begin the process of moving into our larger Group Two study," he said. "Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
The Ocumetics Lens is designed to fit within the natural lens compartment of the eye and utilize the eye's natural muscle activity to shift focus between distances, potentially providing clear vision at all ranges without glasses or contact lenses. The technology aims to offer a differentiated solution for patients seeking improved vision across a broader range of distances.
The initiation of Group Two recruitment is a critical step toward validating the lens's performance in a larger patient cohort. As the company transitions from a safety-focused study to one that measures visual outcomes, it will gather essential evidence to support regulatory approvals and eventual commercialization.
"We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens," said Burns. "At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
The company's progress in clinical trials is closely watched by the ophthalmic industry, as a successful accommodating intraocular lens could disrupt the market for vision correction. With the aging global population and increasing demand for advanced surgical options, the Ocumetics Lens has the potential to address a significant unmet need.
Ocumetics Technology Corp. is a Canadian research and product development company focused on developing advanced vision correction solutions. The company is currently in the first-in-human early feasibility study phase of its technology, which, if proven effective, could transform the field of ophthalmology.
